Wadhane Jitendra 4
4 · Pyxis Oncology, Inc. · Filed Mar 28, 2023
Insider Transaction Report
Form 4
Wadhane Jitendra
Prin Fin & Acct Officer
Transactions
- Award
Common Stock
2023-03-24+29,393→ 118,041 total - Disposition to Issuer
Stock Option (Right to buy)
2023-03-24−157,257→ 0 totalExercise: $8.71Exp: 2031-07-30→ Common Stock (157,257 underlying) - Award
Stock Option (Right to buy)
2023-03-24+157,257→ 157,257 totalExercise: $2.21Exp: 2031-07-30→ Common Stock (157,257 underlying) - Award
Common Stock
2023-03-24+45,000→ 88,648 total
Footnotes (4)
- [F1]Represents restricted stock units that vest 25% on March 24, 2024, and then in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date.
- [F2]Represents restricted stock units that vest 25% on August 3, 2023, and then in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date.
- [F3]In accordance with the terms of the Pyxis Oncology, Inc. 2019 Equity and Incentive Plan (the "Plan"), the Board of Directors of Pyxis Oncology, Inc. approved a stock option repricing pursuant to which option awards granted under the Plan were amended to reduce the exercise price to $2.21 per share, the closing stock price on the date of Board approval. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements.
- [F4]These stock options vested 25% on August 23, 2022, and then vests in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date.